Amgen stock: UBS keeps Buy rating ahead of the Xetra open
Published on 10/26/2026 at 08:26 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSAnalyst view and trading setup
- UBS analyst Michael Yee maintained a Buy rating and a USD 470.00 price target on October 24, 2026.
- Amgen’s investor calendar lists a Q3 2026 earnings call for November 3, 2026.
- Amgen stock trades pre-market at EUR 393.73 at 8:25 a.m. CET at Lang & Schwarz on October 26, 2026.
UBS analyst Michael Yee maintained a Buy rating on Amgen and a USD 470.00 price target in a report dated October 24, 2026, according to Markets Insider. Amgen stock trades pre-market at EUR 393.73 at 8:25 a.m. CET at Lang & Schwarz on October 26, 2026.
UBS keeps its Buy rating
The analyst action applies to Amgen Inc., whose shares trade on Nasdaq under the ticker AMGN. The report identified Yee as the UBS analyst covering Amgen and retained the USD 470.00 target and Buy rating dated October 24, 2026. The report also stated that Amgen shares closed the previous Friday at USD 439.26 on the U.S. market.
Amgen and the day ahead
Amgen develops medicines for patients with serious illnesses and earns revenue from those medicines, according to the company’s investor-relations site. The same site lists an Amgen Q3 2026 earnings conference call for November 3, 2026. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Amgen stock.
Market context: Market report Nasdaq Composite.
